-
The impact of the pandemic on alcohol-related liver disease and liver transplantation, and the emergence of non-alcohol related fatty liver disease (NAFLD) as a public health threat to be featured at International Liver Congress™ 2022 (ILC 2022)
The latest and 57th iteration of International Liver Congress™ (ILC 2022) returns as an in-person event in London this coming June (22–26). The event is being held at the ExCeL London exhibition centre, and online. The congress is convened annually by the European Association for the Study of the Liver (EASL) and is expected to attract some 8,000 researchers, doctors, policymakers, and industry leaders working on liver disease from some 120 countries. The past two iterations of the conference have been held virtually due to the COVID-19 pandemic. For registered delegates unable to attend the in-person event, all sessions will be available digitally. All official onsite press conferences will be broadcast live via Zoom. …
-
EASL Statement on cases of severe acute hepatitis in children of unknown causes
The European Association for the Study of the Liver (EASL) echoes the concerns of UK and WHO Europe officials on this unusual outbreak of severe acute hepatitis in children, originally in Europe, and more recently in Asia and North America. EASL concurs with experts that the common viruses that cause acute viral hepatitis have not been detected in these patients. It is also in agreement with other authorities that at this stage with the information we have, international travel or links to other countries, based on the currently available information, have not been identified as important factors. Collaboration Though these cases are rare events, EASL welcomes the serious consideration of…
-
A-TANGO – An EU-funded clinical Phase II study gives cirrhosis patients new hope
More than ten million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO Consortium will perform Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves liver regeneration. We call this novel combinatorial therapy “G-TAK”. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and selection for novel therapies. Why are novel therapies for ACLF urgently needed? Liver diseases that lead to…
